Obesity

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints

Obesity Recent News

Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China
Novo Nordisk's weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm.
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications.
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
Winfrey dedicated a prime-time special to discussing the stigma surrounding weight loss and the use of drugs like Ozempic and Mounjaro
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
The CMS is reviewing the FDA's action to expand use of Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
Novo Nordisk, a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country.
WeightWatchers Stock Falls After Q4 Results, Oprah Winfrey Exits
Director Oprah Winfrey has decided not to stand for re-election to the WeightWatchers board of directors. She has served on the board since 2015. "I look forward to continuing to advise and collaborate with WeightWatchers and CEO Sima Sistani in elevating the conversation around recognizing obesity as a chronic condition, working to reduce stigma, and advocating for health equity," said Oprah Winfrey.
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Obesity Drug Wegovy Sales Jump 365% In H1 As Novo Nordisk Reports Solid Results, Raises FY23 Guidance
Ozempic Alternatives: These Two Drugs Show Promise In Affordability And Effectiveness For Weight Loss
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.
Banning KFC, McDonald's Near Schools — How Western Australia Plans To Tackle Obesity
Elon Musk Says His Neuralink Chip Could Treat Paralysis, Stroke And Brain Injury
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility. 
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
The FDA has cleared Altimmune Inc's (NASDAQ:
Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades
Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had 
European Authorities Recommend Approval Of Wegovy For Obesity
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. 
See Why Altimmune Stock Plunged After Obesity Trial Data
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
Rhythm Pharma's ImciVree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations
FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know
A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people. 
9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved